Picture of Lexington Biosciences Holdings logo

LXGTF Lexington Biosciences Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-0.35%
3m-3.17%
6m-9.61%
1yr-99.91%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Lexington Biosciences Holdings EPS forecast chart

Profile Summary

Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    March 31st, 2024
    Incorporated
    December 22nd, 2015
    Public Since
    June 1st, 2017
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    27,456,400

    LXGTF Share Price Performance

    Similar to LXGTF

    Picture of Aamaxan Transport logo

    Aamaxan Transport

    us flag iconPink Sheets on Nasdaq

    Picture of ACCUSTEM SCIENCES logo

    ACCUSTEM SCIENCES

    us flag iconPink Sheets on Nasdaq

    Picture of Acutus Medical logo

    Acutus Medical

    us flag iconPink Sheets on Nasdaq

    Picture of ADM Tronics Unlimited logo

    ADM Tronics Unlimited

    us flag iconPink Sheets on Nasdaq

    FAQ